论文部分内容阅读
目的探讨舒必利、奥美拉唑联合铝碳酸镁治疗胆汁反流性胃炎患者对其血清VIP、IL-6水平的影响。方法选取胆汁反流性胃炎患者102例作为研究组,予舒必利、奥美拉唑联合铝碳镁治疗。另选取健康体检者102例作为对照组。分别于用药前、用药后4周清晨空腹静脉抽血检测2组血清中VIP、IL-6水平。结果用药前2组VIP、IL-6水平差异均无统计学意义(P>0.05)。研究组用药4周后VIP、IL-6水平均低于治疗前(P<0.05),但与对照组比较差异无统计学意义(P>0.05)。结论 VIP、IL-6可作为胆汁反流性胃炎疾病做辅助性诊断及疗效的监测,舒必利、奥美拉唑、铝碳酸镁三者联用可降低患者血清中VIP、IL-6水平,具有较好的治疗效果。
Objective To investigate the effects of sulpiride and omeprazole in combination with magnesium aluminum hydride on the serum levels of VIP and IL-6 in patients with bile reflux gastritis. Methods Twenty patients with bile reflux gastritis were selected as study group, treated with sulpiride and omeprazole in combination with aluminum carbon and magnesium. Another 102 healthy subjects were selected as the control group. The levels of VIP and IL-6 in the serum of two groups were measured before fasting and fasting 4 weeks after treatment. Results Before treatment, the levels of VIP and IL-6 in two groups had no significant difference (P> 0.05). After 4 weeks of treatment, the levels of VIP and IL-6 in the study group were lower than those before treatment (P <0.05), but there was no significant difference compared with the control group (P> 0.05). Conclusions VIP and IL-6 can be used as auxiliary diagnosis and curative effect of bile reflux gastritis. Combined use of sulpiride, omeprazole and aluminum magnesium carbonate can reduce the level of VIP and IL-6 in serum of patients with Better therapeutic effect.